Skip to main content

Tecentriq Side Effects

Generic name: atezolizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Oct 9, 2023.

Note: This document contains side effect information about atezolizumab. Some dosage forms listed on this page may not apply to the brand name Tecentriq.

Applies to atezolizumab: intravenous solution.

Serious side effects of Tecentriq

Along with its needed effects, atezolizumab (the active ingredient contained in Tecentriq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking atezolizumab:

More common

Less common

Rare

Incidence not known

Other side effects of Tecentriq

Some side effects of atezolizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to atezolizumab: intravenous solution.

Cardiovascular

Common (1% to 10%): Venous thromboembolism[Ref]

Dermatologic

Very common (10% or more): Rash (15%), pruritus (13%)[Ref]

Endocrine

Frequency not reported: Immune-related thyroid disorders (e.g., hyperthyroidism, hypothyroidism)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (25%), constipation (21%), diarrhea (18%), abdominal pain (17%), vomiting (17%)

Common (1% to 10%): Dehydration, intestinal obstruction[Ref]

General

The most common adverse reactions (greater than 20%) were fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation. The most common Grade 3 to 4 adverse reactions (greater than 2%) were urinary tract infection, anemia, fatigue, dehydration, intestinal obstruction, urinary obstruction, hematuria, dyspnea, acute kidney injury, abdominal pain, venous thromboembolism, sepsis, and pneumonia.[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (22%)

Common (1% to 10%): Urinary obstruction[Ref]

Hematologic

Common (1% to 10%): Anemia, lymphopenia, increased alkaline phosphatase, increased alkaline phosphatase[Ref]

Hepatic

Common (1% to 10%): Acute kidney injury, liver enzyme increase, increased ALT, increased AST

Immunologic

Very common (10% or more): Immune related colitis (19.7%)

Common (1% to 10%): Immune related pneumonitis, immune related hepatitis, sepsis

Frequency not reported: Immune related endocrinopathies[Ref]

Local

Frequency not reported: Infusion related reactions[Ref]

Metabolic

Very common (10% or more): Decreased appetite (26%)

Common (1% to 10%): Hyponatremia, hyperglycemia, hypoalbuminemia[Ref]

Musculoskeletal

Very common (10% or more): Back/neck pain (15%), arthralgia (14%)[Ref]

Nervous system

Frequency not reported: Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barre[Ref]

Ocular

Frequency not reported: Ocular inflammatory toxicity[Ref]

Other

Very common (10% or more): Fatigue (52%), pyrexia (21%), peripheral edema (18%)

Common (1% to 10%): Increased creatinine[Ref]

Psychiatric

Common (1% to 10%): Confusional state[Ref]

Renal

Common (1% to 10%): Hematuria[Ref]

Respiratory

Very common (10% or more): Dyspnea (16%), cough (14%)

Common (1% to 10%): Dyspnea, pneumonia[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Tecentriq (atezolizumab). Genentech. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.